Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2025 Jan 8

PMID 39769318

Authors

Orest Szczygielski

Emilia Dabrowska

Sylwia Niemyjska

Andrzej Przylipiak

Monika Zajkowska

Affiliations

Soon will be listed here.

Abstract

Malignant melanoma is one of the most important dermatological neoplasms. The high mortality rate associated with this skin disease is primarily due to the occurrence of metastases, while the diagnosis and treatment of melanoma in its early stages has a favorable prognosis. Early detection is crucial because the success of treatment is directly related to the depth of cancerous growth. The family of matrix metalloproteinases (MMPs) plays a critical role in the initiation and progression of melanoma. Prominent MMPs, including MMP-1, MMP-2, MMP-3, MMP-9, MMP-13, and MMP-14, have been shown to significantly contribute to the development of melanoma. The tumor microenvironment, particularly the extracellular matrix (ECM), has emerged as a critical factor in modulating cancer progression. This review focuses on the role of matrix metalloproteinases and their inhibitors in ECM degradation and the subsequent progression of melanoma, as well as their potential as therapeutic targets.

References

van der Kooij M, Speetjens F, van der Burg S, Kapiteijn E . Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. Cancers (Basel). 2019; 11(6). PMC: 6627906. DOI: 10.3390/cancers11060845. View

Karamanos N, Theocharis A, Piperigkou Z, Manou D, Passi A, Skandalis S . A guide to the composition and functions of the extracellular matrix. FEBS J. 2021; 288(24):6850-6912. DOI: 10.1111/febs.15776. View

Zhao F, Evans K, Xiao C, DeVito N, Theivanthiran B, Holtzhausen A . Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma. Cancer Immunol Res. 2018; 6(12):1459-1471. PMC: 6279598. DOI: 10.1158/2326-6066.CIR-18-0086. View

Ene C, Nicolae I, Ene C . Angiogenic systemic response to the hypoxic microenvironment in prostate tumorigenesis: A pilot study. Exp Ther Med. 2023; 26(4):483. PMC: 10518656. DOI: 10.3892/etm.2023.12182. View

Vandenbroucke R, Libert C . Is there new hope for therapeutic matrix metalloproteinase inhibition?. Nat Rev Drug Discov. 2014; 13(12):904-27. DOI: 10.1038/nrd4390. View

Afshar K, Sanaei M, Ravari M, Pourbagheri-Sigaroodi A, Bashash D . An overview of extracellular matrix and its remodeling in the development of cancer and metastasis with a glance at therapeutic approaches. Cell Biochem Funct. 2023; 41(8):930-952. DOI: 10.1002/cbf.3846. View

Zarrabi K, Dufour A, Li J, Kuscu C, Pulkoski-Gross A, Zhi J . Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem. 2011; 286(38):33167-77. PMC: 3190951. DOI: 10.1074/jbc.M111.256644. View

Shi Y, Ma X, Fang G, Tian X, Ge C . Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges. NanoImpact. 2022; 21:100293. DOI: 10.1016/j.impact.2021.100293. View

Rivera S, Khrestchatisky M, Kaczmarek L, Rosenberg G, Jaworski D . Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?. J Neurosci. 2010; 30(46):15337-57. PMC: 3072038. DOI: 10.1523/JNEUROSCI.3467-10.2010. View

10.

Mastalier Manolescu B, Lazar A, Tiplica G, Zurac S, Rebosapca A, Andreescu B . MMP1, MMP9, MMP11 and MMP13 in melanoma and its metastasis - key points in understanding the mechanisms and celerity of tumor dissemination. Rom J Morphol Embryol. 2024; 65(1):45-52. PMC: 11146457. DOI: 10.47162/RJME.65.1.06. View

11.

Song K, Yu Z, Zu X, Li G, Hu Z, Xue Y . Collagen Remodeling along Cancer Progression Providing a Novel Opportunity for Cancer Diagnosis and Treatment. Int J Mol Sci. 2022; 23(18). PMC: 9502421. DOI: 10.3390/ijms231810509. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Alaseem A, Alhazzani K, Dondapati P, Alobid S, Bishayee A, Rathinavelu A . Matrix Metalloproteinases: A challenging paradigm of cancer management. Semin Cancer Biol. 2017; 56:100-115. DOI: 10.1016/j.semcancer.2017.11.008. View

14.

Niland S, Eble J . Hold on or Cut? Integrin- and MMP-Mediated Cell-Matrix Interactions in the Tumor Microenvironment. Int J Mol Sci. 2020; 22(1). PMC: 7794804. DOI: 10.3390/ijms22010238. View

15.

Xia Y, Wu S . Tissue inhibitor of metalloproteinase 2 inhibits activation of the β-catenin signaling in melanoma cells. Cell Cycle. 2015; 14(11):1666-74. PMC: 4614343. DOI: 10.1080/15384101.2015.1030557. View

16.

Wei M, Liu X, Cao C, Yang J, Lv Y, Huang J . An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma. BMB Rep. 2018; 51(11):572-577. PMC: 6283027. View

17.

Pach E, Kumper M, Fromme J, Zamek J, Metzen F, Koch M . Extracellular Matrix Remodeling by Fibroblast-MMP14 Regulates Melanoma Growth. Int J Mol Sci. 2021; 22(22). PMC: 8625044. DOI: 10.3390/ijms222212276. View

18.

Dhanyamraju P, Patel T . Melanoma therapeutics: a literature review. J Biomed Res. 2022; 36(2):77-97. PMC: 9002155. DOI: 10.7555/JBR.36.20210163. View

19.

Hadler-Olsen E, Fadnes B, Sylte I, Uhlin-Hansen L, Winberg J . Regulation of matrix metalloproteinase activity in health and disease. FEBS J. 2010; 278(1):28-45. DOI: 10.1111/j.1742-4658.2010.07920.x. View

20.

Nagase H, Visse R, Murphy G . Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69(3):562-73. DOI: 10.1016/j.cardiores.2005.12.002. View